Health Care Weekly: FDA, Lilly Debate Jurisdiction in Retatrutide Case; Interim Pathway for Wellness Peptide Compounding Mulled; CMS Gains Power to Ban Companies from Government Health Care Programs; Rule Proposed to Implement PBM Reimbursement Law

The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. Key stories we’re following this week include: • Court considers whether Lilly’s challenge to GLP-1 ingredient classification can proceed. • FDA seeks pathway for compounding unapproved wellness peptides ahead of final rulemaking. […]

Published on Oct 21, 2026

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

Copyright ©2026 The Capitol Forum. All Rights Reserved.